BPC-157 oral vs injection: what the studies show

Answer first

Most BPC-157 research used injections, and the measurements found of how the body handles it are from injected rats and dogs. In the sources reviewed, swallowed forms appear in three animal studies that also used injections and in one human tablet trial without results. Neither form is approved as a medicine, and no comparison in people could be found.

At a glance

How each form reaches the body

The two forms take very different paths, and only one of them has been measured. Everything below comes from animals or from single reports in people.

Injection. Most animal studies injected the peptide into the abdominal cavity (intraperitoneal injection) ^[1]. Others injected it into muscle or placed it directly into a bone defect, as in a rabbit study ^[2]. In people, the published reports describe injections into the knee joint ^[3] and around the inflamed area of the bladder during a camera examination ^[4].

What the body does with an injection. One independent group in China followed a traceable version of the molecule in rats and beagle dogs. It was given into a vein or into muscle ^[5]. The body cleared half of it in under 30 minutes, breaking it down into fragments and single building blocks, removed mainly through urine and bile ^[5].

How much of an injection arrives. The comparison was with injection into a vein. After injection into muscle, about 14 to 19 per cent reached the bloodstream in rats and about 45 to 51 per cent in dogs ^[5]. No such measurement in people could be found in the sources reviewed for this page.

Swallowing. The originating group in Zagreb describes the peptide as "native and stable in human gastric juice for more than 24 h" ^[6]. That claim explains the name "stable gastric pentadecapeptide" and the use of drinking water or a stomach tube in some animal work.

What is not known about swallowing. No independent confirmation of that stability claim could be found in the sources reviewed. A 2026 review repeats the stability description, but finds that no pharmaceutical-grade formulation has been developed or validated ^[7]. It also reports that how readily the peptide passes through tissue barriers (permeability) has not been characterised ^[7]. The measurements of how the body handles the peptide cover the vein and muscle routes only. No figure for how much of a swallowed dose reaches the blood could be found ^[5].

In animals, swallowed doses were given in drinking water, for example ^[8], or by tube straight into the stomach, known as intragastric delivery ^[9], ^[10]. Whether a swallowed dose acts in the gut itself or after absorption could not be settled from the sources reviewed.

The core difference is therefore one of knowledge. For injection there are animal measurements of how fast the peptide disappears. For swallowing there is a stability claim from one group and no measured uptake.

What the studies show

Animal studies that used both forms

Head-to-head, animal Three animal studies gave the peptide by injection and by mouth or stomach tube within one experiment. No study comparing the two forms directly in people could be found in the sources reviewed for this page.

Head-to-head, animal In rats under 48 hours of restraint stress, the peptide was given into the abdominal cavity or by stomach tube. Both routes were reported to protect the stomach lining. Three other drugs given alongside cancelled the effect of both routes ^[9].

Head-to-head, animal In that same study, the beta blocker atenolol cancelled only the injected effect. The beta blocker propranolol affected only the effect of the stomach-tube dose ^[9]. The authors concluded that the role of this receptor type appears to depend on the route ^[9].

Head-to-head, animal An independent group in China tested stomach ulcers in rats against the established stomach drug famotidine. Ulcers were held back by 45.7% to 65.6% at two doses, with both routes ^[10]. The authors reported a larger effect after injection into muscle than after delivery into the stomach ^[10].

Head-to-head, animal In rats with a surgically cut knee ligament, the peptide was given into the abdominal cavity, in drinking water or as a cream. Over 90 days, improvements in function, strength and tissue were reported for all three routes ^[8]. The abstract does not state group sizes.

These three studies are all in rats, in injuries of the stomach or a ligament. None of them measured how much of the peptide reached the blood by each route.

Swallowed forms in people

Registered trial One early-stage trial planned to test tablets of 1 mg in 42 healthy volunteers, with single and repeated doses over 14 days ^[11]. It was meant to measure safety and how the body handles the peptide. Its entry has not been updated since 17 December 2015, and no result has been posted ^[11].

Registered trial A completed study in 40 people tested a chewable sweet containing several ingredients rather than the peptide on its own ^[12]. No result is posted in the register. Even a result would say little about BPC-157 alone.

No published result in people for any swallowed form could be found in the sources reviewed for this page.

Injected forms in people

Case series A clinic looked back through its files on patients injected in the knee for pain. It reached 16 of 17 of them by telephone. Twelve had been given BPC-157 alone, and 11 of those said they had improved markedly ^[3].

Case series That report had no comparison group and no properly tested questionnaire. A 2026 overview calls it flawed in the way it was conducted ^[13].

Case series In 12 women with a painful bladder condition, the peptide was injected once during a camera examination. Symptoms disappeared in 10 and improved by 80% in the other 2 ^[4]. Without a comparison group, the passage of time cannot be ruled out as the cause.

Overall appraisal A 2025 narrative review counts three small pilot studies in people ^[14]. They are the knee report, the bladder report and a study of safety and handling after giving it into a vein ^[14]. A 2025 systematic review sifted 544 articles, kept 36 and found only 1 involving patients ^[15].

Why the results cannot be set against each other

The human reports on injection and the registered tablet trial differ in population, dose, endpoint and length. The tablet trial has no result at all. Their figures cannot be weighed against each other.

The animal studies with both routes used doses per kilogram of body weight or concentrations in water. Those units do not translate into one another, and none of it transfers directly to people. Nearly all the animal work comes from a single group in Zagreb ^[16].

Doses used in the studies

The doses below are simply what the cited studies gave, listed so that the results can be understood. They are not advice on how to use anything.

The tablet row is only what a registry entry planned, and that study has posted no result. The bladder row describes a single procedure carried out by the investigators. No country has an approved dose for either form, because no country has an approved product.

Safety and side effects

No controlled safety data in people could be found for either form.

Swallowed forms

• No safety result from the tablet trial. The one study designed to produce human safety data for tablets has posted nothing since 2015 ^[11].
• No stomach or gut side-effect data. No report of digestive complaints after swallowing the peptide could be found in the sources reviewed for this page.

Injected forms

• No side effects reported in two small series. With 16 and 12 patients and no comparison group, that says nothing about safety ^[3], ^[4].
• No data on repeated injection. No study of long-term or repeated injection in people could be found in the sources reviewed ^[14].

Both forms

• The route matters to the regulator. The American regulator names a risk of immune reactions "for certain routes of administration" and unresolved impurities ^[18].
• No toxicology report found. The originating group states that no dose proved lethal, but only as an aside in its papers ^[6].
• Untested risks. No study of whether the peptide can cause cancer or damage genetic material could be found ^[14], ^[19]. Its proposed effect on vessel growth raises unanswered questions about hidden tumours ^[14], ^[19].

The regulator's own wording applies to every route proposed to it:

"FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans." ^[18]

Material made outside regulated manufacturing carries no guarantee of identity, purity or freedom from germs, whatever its form ^[18]. A 2025 commentary describes the substance as unregulated and freely available online ^[20]. This page does not rank the two forms, and missing data are not evidence of safety.

Legal status

Switching between forms

No study of switching from one form to the other, or of using both at once, could be found in the sources reviewed for this page. The ligament study gave each route to a separate group of rats ^[8].

No conversion between the forms can be taken from the sources. Rats received drinking water at a set concentration, while the tablet trial planned whole tablets. The two figures are not comparable, and this page gives no amounts and no schedule.

The directory lists several products that contain BPC-157, among them the BPC-157 + TB-500 Blend. One entry describes its product as "sold as one vial". No swallowable product is listed there.

The anti-doping ban names the substance, not a form. The 2026 list names BPC-157 in section S0, at all times ^[21]. It has been named on the list since 1 January 2022 ^[22]. More is at peptides banned in sport.

Australia lists the substance by name, and possessing it there without official permission has been against the law since 1 June 2024 ^[23]. The full record is in the BPC-157 monograph.

Frequently asked questions

Does BPC-157 work orally?

In rats, swallowed or stomach-tube doses were reported to protect the stomach lining and to improve healing of a cut knee ligament. In people, the only registered tablet trial has posted no result since 2015. No result showing whether a swallowed dose works in people could be found in the sources reviewed for this page.

Which is better, oral BPC-157 or BPC-157 injections?

Neither can be called better on the evidence. In one rat study of stomach ulcers, the authors reported a larger effect after injection into muscle than after delivery into the stomach. In a rat ligament study, improvement was reported with injection and with drinking water, without a ranking of the two. No comparison of the two forms in people could be found.

Is oral or injected BPC-157 safer?

That cannot be answered. No controlled safety data in people could be found for either form. Two small injection reports with 16 and 12 patients mention no side effects, which says nothing about safety. The tablet trial has posted no result. The American regulator links the risk of immune reactions to the route used.

What is the difference between oral BPC-157 and BPC-157 injections?

The substance is the same, but the path and the evidence differ. Injections were used in most animal work and in both published human reports. In rats and dogs, the body clears half an injected dose in under 30 minutes. For swallowed forms there is a stability claim from one group and no measured uptake.

Can oral and injected BPC-157 be used together?

This page answers only what the research shows, not how to use anything. No study of switching between the forms or of using both could be found in the sources reviewed for this page. In the ligament study, each route went to a separate group of rats.

Is BPC-157 stable in stomach acid?

The originating group in Zagreb describes it as stable in human gastric juice for more than 24 hours. No independent test of that claim could be found in the sources reviewed. A 2026 review repeats the description but notes that no pharmaceutical-grade formulation has been developed or validated.

How much oral BPC-157 reaches the blood?

No figure could be found in the sources reviewed for this page. The only measurements come from rats and dogs given the peptide into a vein or into muscle. After injection into muscle, about 14 to 19 per cent reached the bloodstream in rats and about 45 to 51 per cent in dogs.

Are BPC-157 tablets or capsules approved anywhere?

No. No form of BPC-157 is approved as a medicine in any market examined, as checked on 6 September 2026. Australia lists the substance by name as prescription-only and restricts possession without official permission.

Is oral BPC-157 banned in sport?

Yes. The anti-doping list names the substance, not a form, and bans it at all times in section S0. It has been named there since 1 January 2022.